Herantis Pharmas clinical study with CDNF in Parki

Herantis Pharma's clinical study with CDNF in Parkinson's disease authorized in Sweden

Herantis Pharma Plc Company release 23 March 2017 at 12:30 pm

The Medicines Agency of Sweden, MPA, has authorized Herantis Pharma Plc's ("Herantis") first-in-human clinical study of the company's investigational product CDNF for the treatment of Parkinson's disease. Patient recruitment in the randomized, placebo-controlled Phase 1-2 clinical study is planned to begin in Sweden in the first half of 2017.

"CDNF is a novel neurotrophic and neuroprotective factor, which affects several mechanisms relevant to Parkinson's disease", explains  Sigrid Booms , Herantis' Director, Clinical Development. "Based on preclinical data CDNF holds a great promise for a significant improvement over currently available treatments. We are really excited to proceed to this first clinical study."

"Parkinson's disease is a tremendous financial burden to societies in addition to the human suffering", says  Pekka Simula , CEO of Herantis. "Known drugs only alleviate motor symptoms until further disease progression. Our ambition is to slow down, stop, hopefully even reverse the progression of the disease. CDNF is a promising novel drug candidate, which works via several relevant biological mechanisms that also clearly differentiate it from conventional neurotrophic factors. This regulatory approval marks a very important milestone in our development."

The first study site to start patient recruitment will be Karolinska University Hospital in Stockholm, Sweden. Two other university hospitals are planned to join the study later in 2017.  The clinical study intends to recruit in total 18 patients with Parkinson's disease. 

Further information:

Herantis Pharma Plc, Pekka Simula, CEO, telephone: +358 40 7300 445 Company web site: www.herantis.com Certified Advisor: UB Securities Ltd, telephone: +358 9 25 380 225

About Parkinson's disease

Parkinson's disease is a slowly progressing neurodegenerative disease caused by the death of dopaminergic neurons in the midbrains. Common first motor symptoms of the disease include tremors, rigidity and slowness of movement. While the motor symptoms can be treated with medication the disease progression cannot be prevented, and the benefits of medication may be lost with disease progression or side effects can become unmanageable. In addition, Parkinson's disease may cause non-motor symptoms such as sleep problems, depression, and anxiety, which are not alleviated by current Parkinson's drugs. Estimated 7 million people worldwide have Parkinson's disease.

About CDNF

CDNF, or Cerebral Dopamine Neurotrophic Factor, is an endoplasmic reticulum located and secreted protein with neuroprotective and neurorestorative properties, patented worldwide by Herantis.  Encouraged by strong preclinical proof-of-concept Herantis is launching a first-in-human, randomized Phase 1-2 clinical study with CDNF for the treatment of Parkinson's disease (PD) in 1H/2017. The clinical study has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement number 732386.

In preclinical studies including chronic toxicology studies, CDNF administration has been safe; CDNF has protected and regenerated midbrain dopamine-generating cells suggesting a potential for disease modification of PD; it has also shown efficacy in non-motor symptoms in PD. In an ALS disease model CDNF has significantly increased survival and reduced symptoms. This suggests the potential to address unmet clinical needs in both PD and ALS. CDNF is based on research at the Institute of Biotechnology at the University of Helsinki, lead by professor  Mart Saarma . 

About drug development in general

Drug development projects can usually be divided in two stages: The preclinical stage, and the clinical stage involving human subjects. The clinical stage can be further broken in three formal phases. Phase 1 clinical studies assess the safety of a drug candidate in human subjects. In Phase 2, the optimal dosing and possible efficacy in the treatment of a particular disease is studied. Phase 3 studies finally aim to establish a statistical proof of safety and efficacy of the drug candidate in typically hundreds or thousands of patients for market approval. Drug development can take 10-15 years from the first preclinical studies to market approval.

About Herantis Pharma Plc

Herantis Pharma Plc is an innovative drug development company focused on regenerative medicine for breakthrough in unmet clinical needs. Our first-in-class assets are based on globally leading scientific research in their fields: CDNF for disease modification in neurodegenerative diseases, primarily Parkinson's and ALS; and Lymfactin for breast cancer associated lymphedema, with potential also in other lymphedemas. The shares of Herantis are listed on the First North Finland marketplace run by Nasdaq Helsinki stock exchange.

Distribution:

Nasdaq Helsinki Main media www.herantis.com